B
Bull
Bull · 25%SION
$19.38
Precio del escenario
$6.460
+0.461 (+7.13%)Al cierre
Loading chart…
- High
- 6.480
- Open
- 5.950
- VWAP
- 6.29
- Vol
- 1.40M
- Mkt Cap
- —
- Low
- 5.930
- Amount
- 8.83M
- EV/EBITDA, TTM
- 0.00
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
AI analysis of Sionna Therapeutics Inc (SION)
sellSionna Therapeutics is not a good buy right now due to significant financial losses and negative market sentiment. The stock is currently priced at $5.87, but it has seen a staggering 87.55% decline over the past 20 days and a 90% drop following the failure of its clinical trial. Additionally, the RSI is at 21.701, indicating the stock is oversold, but this does not outweigh the risks.
Métricas de valoración
The current forward P/E ratio for Sionna Therapeutics Inc (SION) is 0.00, compared to its 5-year average forward P/E of -10.50.
Alphio AI Price Scenarios for SION
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SION
Cronología de eventos
Noticias
7.008-27PRnewswirePomerantz Investigates Sionna Therapeutics for Securities Fraud
7.008-27PRnewswireSionna Therapeutics Under Investigation for Securities Violations
6.008-25NASDAQ.COMSionna Therapeutics Stock Surpasses Analyst Target Price
8.508-20FoolVertex Pharmaceuticals Maintains Dominance in Cystic Fibrosis Market
7.008-20PRnewswireRobbins LLP Investigates Sionna Therapeutics After 92% Stock Plunge
SION FAQ — answered by Alphio AI
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity. It operates in the Healthcare sector.
Sionna Therapeutics is not a good buy right now due to significant financial losses and negative market sentiment. The stock is currently priced at $5.87, but it has seen a staggering 87.55% decline over the past 20 days and a 90% drop following the failure of its clinical trial. Additionally, the RSI is at 21.701, indicating the stock is oversold, but this does not outweigh the risks.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.